/

Società

Or

Non verificato

Orca Bio

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaOncologiaSalute

20 comunicati stampa

Guarda tutti i comunicati

28/04/2026

Industria

Oncologia

Igiene alimentare

Salute

Medicina - Varie

Farmaceutica

Biotecnologia

Orca Bio Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Orca-Q® for the Treatment of High-Risk Hematologic Malignancies

Fonte

Emittente

1.00

0

01/04/2026

Industria

Biotecnologia

Farmaceutica

Salute

Oncologia

Orca Bio Announces FDA Review Extension of BLA for Orca-T for the Treatment of Hematologic Malignancies

Fonte

Emittente

1.00

0

02/03/2026

Eventi

Industria

Oncologia

Salute

Biotecnologia

Sanità

Medicina - Varie

Farmaceutica

Orca Bio to Present Clinical Data on Its Pipeline of High-Precision Cell Therapies at the 52nd Annual Meeting of the EBMT

Fonte

Emittente

1.00

0

05/02/2026

Biotecnologia

Farmaceutica

Salute

Oncologia

Industria

Orca Bio Presents New Data at the 2026 Tandem Meetings of ASTCT® and CIBMTR® Reinforcing Orca-T® as a Durable, High-Precision Cell Therapy for Hematological Malignancies

Fonte

Emittente

1.00

0

21/01/2026

Scienza

Biologia

Biotecnologia

Farmaceutica

Oncologia

Salute

Medicina - Varie

Eventi

Industria

Orca Bio to Present New Clinical Data on Its High-Precision Cell Therapies at the 2026 Tandem Meetings of ASTCT® and CIBMTR®

Fonte

Emittente

1.00

0

09/01/2026

Oncologia

Salute

Biologia

Sanità

Farmaceutica

Biotecnologia

Orca Bio Announces $250M in Aggregate Financing in Preparation for Potential Commercialization

Fonte

Emittente

1.00

0

05/01/2026

Eventi

Web e Social Network

Salute

Biologia

Farmaceutica

Oncologia

Orca Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

Fonte

Emittente

1.00

0

15/12/2025

Industria

Oncologia

Salute

Biologia

Medicina - Varie

Farmaceutica

Biotecnologia

Orca Bio Announces Orca-T® Phase 3 Data Published in Blood Demonstrate Significant Improvement in Survival Free from Chronic Graft versus Host Disease in Patients with Hematological Malignancies

Fonte

Emittente

1.00

0

08/12/2025

Industria

Biotecnologia

Salute

Farmaceutica

Medicina - Varie

Oncologia

Orca Bio Presents New Clinical Data on its Pipeline of High-Precision Cell Therapies including Orca-Q® Without GvHD Prophylaxis and Orca-T/CAR-T Combination Therapy at the 67th ASH Annual Meeting

Fonte

Emittente

1.00

0

06/12/2025

Eventi

Fiere

Industria

Scienza

Biotecnologia

Medicina - Varie

Biologia

Sanità

Farmaceutica

Salute

Oncologia

Orca Bio Presents New Clinical Data on Orca-T® in Older Patients Using Reduced Intensity Conditioning Plus New Analyses from the Precision-T Phase 3 Study at the 67th ASH Annual Meeting

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0